AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB Total Current Liabilities
All obligations due within one year.
AnaptysBio, Inc.NASDAQ: ANAB
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 5.3% from a year ago
Total current liabilities stood at $41.7M at the end of Q1 FY2026, down 5.3% from a year earlier and up 8.0% from the prior quarter. Over 3 fiscal years it compounded at +14.0% a year.
Context
- Total current liabilities amounted to 12.6% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -5.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 38.63M USD
- Year-over-year change
- -15.0%
- 4-year CAGR
- +24.5%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.63M | -15.0% |
| FY2024 | 2024-12-31 | 45.43M | +21.3% |
| FY2023 | 2023-12-31 | 37.44M | +43.7% |
| FY2022 | 2022-12-31 | 26.05M | +61.8% |
| FY2021 | 2021-12-31 | 16.1M | — |
Total Current Liabilities vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's Mar 2026 total current liabilities of $41.7M is the 4th highest of the 10 companies compared; the peer median is $34.39M.
- Its year-over-year change of -5.3% is the 7th highest of 10, against a peer median of +27.2%.
- Total current liabilities amounts to 12.6% of total assets for ANAB, versus a peer median of 13.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $104.02M | +64.5% | +34.1% | 13.7% | |
| Jun 2026 | $81.87M | -14.8% | +14.5% | 11.3% | |
| Mar 2026 | $46.11M | +92.3% | +81.0% | 11.5% | |
| Mar 2026 | $41.7M | -5.3% | +14.0% | 12.6% | |
| Mar 2026 | $35.94M | +7.1% | +24.0% | 13.7% | |
| Jun 2026 | $34.39M | +71.1% | +55.2% | 2.8% | |
| Mar 2026 | $27.37M | +27.2% | +9.3% | 13.8% | |
| Dec 2025 | $13.61M | +60.9% | -4.5% | 24.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.88M | -10.8% | -20.1% | 10.3% |
| Mar 2026 | $10.67M | -26.8% | -41.9% | 16.8% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ANAB) | $34.39M | +27.2% | +14.5% | 13.7% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 495.73M | 71.31M | 35.97M | 123.08M | 238.2M |
| Short-term Investments | 52.37M | 369.93M | 354.94M | 262.29M | 73.44M |
| Net Receivables | 876K | 1.42M | 6.85M | 40.77M | 33.85M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.55M | 9.08M | 5.74M | 4.76M |
| Total Current Assets | 553.88M | 447.21M | 406.84M | 431.88M | 350.25M |
| Property, Plant & Equipment (Net) | 21.84M | 19.99M | 18.27M | 16.23M | 13.89M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 67.1M | 142.94M | 27.03M | 35.47M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 256K | 256K | 256K | 256K | 256K |
| Total Non-current Assets | 89.19M | 163.18M | 45.55M | 51.96M | 14.15M |
| Total Assets | 643.07M | 610.38M | 452.39M | 483.83M | 364.4M |
| Account Payables | 1.74M | 2.78M | 4.7M | 4M | 3.87M |
| Short-term Debt | 0 | 0 | 0 | 1.93M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.18M | 5.38M | 23.77M | 31.05M | 11.09M |
| Total Current Liabilities | 16.1M | 26.05M | 37.44M | 45.43M | 38.63M |
| Long-term Debt | 0 | 0 | 0 | 353.43M | 12.03M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 251.09M | 304.41M | 310.81M | 0 | 276.53M |
| Total Non-current Liabilities | 270.54M | 322.23M | 326.84M | 367.54M | 288.56M |
| Total Liabilities | 286.64M | 348.28M | 364.29M | 412.97M | 327.19M |
| Common Stock | 28K | 29K | 27K | 30K | 28K |
| Retained Earnings | (321.75M) | (450.48M) | (614.1M) | (759.33M) | (772.56M) |
| Accumulated OCI | (422K) | (5.25M) | (797K) | 305K | (24K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 356.43M | 262.1M | 88.1M | 70.87M | 37.21M |
| Total Debt | 20.96M | 19.45M | 17.81M | 369.46M | 14.11M |
| Net Debt | (474.77M) | (51.86M) | (18.15M) | 246.38M | (224.08M) |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.